AlloCure, Inc. is a privately held, clinical-stage biotechnology company focused on the treatment of kidney disease. The company is a leader in the AKI field and is pioneering the development of the first effective therapy for the treatment of AKI.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/02/12 | $25,000,000 | Series B |
Lundbeckfond Ventures | undisclosed |
